Product Images Valsartan

This is a description of the medication which is in the form of a film-coated tablet containing 320 mg of valsartan, USP. The usual dosage and storage instructions are also provided along with manufacturing and prescribing information. The medication needs to be kept in a tight container protected from moisture and out of the reach of children. The information pertains to tablets produced by ScieGen Pharmaceuticals in Hauppauge, NY 11788.*

This is a medication description for a container of 320 g of H St Taber Contas, with an NDC number of 50228-132-30. The medication is ValSartan, in tablet form, and the usual dosage is not available, as it is recommended to read the accompanying prescription information. The container consists of 30 tablets and should be kept at a suitable temperature to protect it from moisture. The medication should be kept out of children's reach. It is intended for prescription only and is produced by ScieGen Pharmaceuticals, located in Hauppauge, NY.*

Each tablet contains 160 mg of valsartan and is coated with fim. The usual dosage and prescribing information should be read before consuming. The tablets should be stored at room temperature and protected from moisture in a tight container. It is important to keep the medication out of reach of children. The tablets are manufactured by Scieen Pharmaceuticals and are available in a bottle of 1000 tablets with a prescription.*

This is a description of a medication containing 160mg of Valsartan, with dosage instruction found on the accompanying prescription. The medication should be stored at a temperature of 68-77°F, with excursions allowed between 59-86°F. It should be protected from moisture and dispensed in a tight container. The manufacturer is Scioen Pharmaceuticals located in Hauppage, NY. The description also includes a warning to keep the medication out of reach of children.*

This is a description of a medicine called Valsartan. Each tablet is coated in a film and contains 80mg of the active ingredient. The recommended dosage is provided in the accompanying information. The tablets should be stored at an average temperature of 20°-25°C, however, temperatures between 15° and 30°C are permitted. This medication should be kept away from moisture in a tightly sealed container, inaccessible from children. This medicine is manufactured by ScieGen Pharmaceuticals, Inc in Hauppauge, NY, and contains 1,000 Tablets.  Furthermore, this medicine is only available upon prescription.*

This is a medication containing 80 mg of Valsartan in tablet form. The usual dosage is advised to be read from the prescription. It should be stored between 15°C to 30°C (59°F to 86°F) with protection from moisture, and kept away from children. This medication is available in the form of 30 tablets and is manufactured by ScieGen Pharmaceuticals in Hauppauge, NY.*

This is a description of a medication containing 40mg of valsartan per film-coated tablet. It comes in a container and should be stored between 20-25°C, with excursions permitted between 15-30°C (See USP Controlled Room Temperature). The medication should be protected from moisture and kept in a tight container (USP). Dosage instructions are included with the prescription information. This medication is only available through prescription and manufactured by ScieGen Pharmaceuticals, Inc. in Hauppauge, NY. Keep out of the reach of children. No errors were detected.*

Each film-coated tablet contains 40 mg of valsartan, a medication commonly used to treat high blood pressure and heart failure. The National Drug Code (NDC) for this product is 50228-135-30. It is recommended to store the tablets at a temperature of 20-25% (68-77 degrees Fahrenheit) and protect them from moisture. The medication should be kept in a tight container and out of reach of children. The indicated usual dosage is not provided. The tablets come in a bottle of 30 and are available only with a prescription. This product is manufactured by Scion Pharmaceuticals in Hauppauge, NY.*

The given text seems to be a table that shows different subgroups of patients and their percentages in the VALIAN study. It also includes the effects of Valsartan and Captopril on mortality in these subgroups. The subgroups are categorized based on age (<65y and =65y), gender (male and female), race (Caucasian and non-Caucasian), and the use of beta-blockers (with beta-blocker and without beta-blocker). Any other information about the study and its results is not available due to incomplete information.*